SCHEDULE 13G Filed 2026-09-18 Event — SEC 0000921895-26-002587 →

BIOTECHNOLOGY VALUE FUND L P → Alector, Inc. ALEC

Stake: — Shares: — CUSIP: 014442107 Class: Common Stock

Composite Decision Signal · PASS (LOW BASE-RATE EDGE) Conviction Score: 21/100 · Filer 90d Win Rate: 25% · Hist. 90d Edge: -8.2%

Filer track record (6 filings): 25% 90d win rate, +0.0% 90d edge
Material 8-K governance/transaction event (Item 5.02 / 1.01 / 2.01) within ±30d
Held by 1 tracked 13F institutional manager
7 NPORT-P mutual funds holding CUSIP
Short interest building (+66.8% vs prior settlement)

Item 4 — Purpose of Transaction

Not extracted from this filing — typically because it's an amendment (13D/A) and Item 4 is unchanged from the parent filing. Read the raw SEC filing →

Cross-References

Insider Activity (last 365d)

0 transactions

0 buys · 0 sales · 0 awards/exercises

Issuer Cluster

10 13D/G filings on this issuer

9 other filings besides this one

Filer Track Record

45 filings by this filer

44 other filings in the data moat

Short Interest · settle 2026-10-15

DTC 1.00

10,254,239 shares short · +66.8% vs prior

Institutional Consensus · 2025-12-31

Held by elite portfolio managers

1 holder · $36K

Point72 Asset Mgmt

Other 13D/G Filings on Alector, Inc.

Filed	Form	Filer	Stake	Shares
2026-10-26	SCHEDULE 13G	RA CAPITAL MANAGEMENT, L.P.	—	—	view →
2026-10-23	SCHEDULE 13G	Deep Track Capital, LP	—	—	view →
2020-07-10	SC	ORBIMED ADVISORS LLC	—	—	view →
2020-06-04	SC	ORBIMED ADVISORS LLC	—	—	view →
2020-03-04	SC	ORBIMED ADVISORS LLC	—	—	view →
2020-02-05	SC	ORBIMED ADVISORS LLC	—	—	view →
2020-01-13	SC	ORBIMED ADVISORS LLC	—	—	view →
2019-12-19	SC	ORBIMED ADVISORS LLC	—	—	view →
2019-08-12	SC	ORBIMED ADVISORS LLC	—	—	view →

Other Filings by BIOTECHNOLOGY VALUE FUND L P

Filed	Form	Issuer	Stake	Shares
2026-10-21	SCHEDULE 13G	Frazier Life Sciences Acquisition Corp. II	—	—	view →
2026-10-16	SCHEDULE 13D/A	Olema Pharmaceuticals, Inc.	9.80%	5,946,981	view →
2026-09-21	SCHEDULE 13G	Tyra Biosciences, Inc.	—	—	view →
2026-08-04	SCHEDULE 13D	Entera Bio Ltd.	9.99%	9,171,741	view →
2026-07-20	SCHEDULE 13G	Research Alliance Corp IV	—	—	view →
2026-07-16	SCHEDULE 13D/A	XOMA Royalty Corp	—	0	view →
2026-07-10	SCHEDULE 13G	Pyxis Oncology, Inc. PYXS	—	—	view →
2026-06-29	SCHEDULE 13D/A	MoonLake Immunotherapeutics MLTX	19.70%	8,302,735	view →
2026-06-26	SCHEDULE 13D/A	Kymera Therapeutics, Inc. KYMR	6.30%	2,712,852	view →
2026-06-04	SCHEDULE 13G	Q32 Bio Inc. QTTB	—	—	view →
2026-05-29	SCHEDULE 13G	Research Alliance Corp III RACC	—	—	view →
2026-05-27	SCHEDULE 13G	OnKure Therapeutics, Inc. OKUR	—	—	view →
2026-05-18	SCHEDULE 13D/A	XOMA Royalty Corp XOMAP	—	3,635,758	view →
2026-04-02	SCHEDULE 13D/A	MoonLake Immunotherapeutics MLTX	22.30%	8,302,735	view →
2025-11-24	SCHEDULE	Repare Therapeutics Inc.	24.00%	10,333,600	view →
2025-05-20	SCHEDULE	XOMA Royalty Corp XOMAP	21.60%	2,590,303	view →
2025-01-28	SCHEDULE	XOMA Royalty Corp XOMAP	25.30%	2,983,026	view →
2024-10-08	SC	MoonLake Immunotherapeutics MLTX	—	—	view →
2024-07-19	SC	Inventiva S.A. IVEVF	—	—	view →
2024-01-29	SC	Rain Oncology Inc.	—	—	view →

Showing 20 of 44

Want this depth on every filing the moment it hits SEC EDGAR?

Free $0 (48h-delayed alerts) · Individual $49/mo (real-time) · Team & API $199/mo · Enterprise.

See pricing →